Protara Therapeutics, Inc. (TARA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 15, 2025, reports on the completion of a public offering of common stock by Protara Therapeutics, Inc., a Delaware corporation. The filing details the full exercise of an underwriters' option related to an offering that initially closed on December 8, 2025.
Key Financial Metrics
- Gross Proceeds: Approximately $86.3 million from the aggregate offering (Firm Shares and Option Shares).
- Offering Price: $5.75 per share.
- Total Shares Issued: 15,000,000 shares (13,043,479 Firm Shares + 1,956,521 Option Shares).
- Net Proceeds: Not explicitly stated; gross proceeds are before deducting underwriting fees and offering expenses.
- Revenue/Profit/Cash Flow: This filing does not provide operational financial metrics such as revenue, net income, operating cash flow, or debt levels.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the full exercise of the underwriters' option on December 15, 2025. This action increased the total shares sold in the offering by approximately 15% compared to the initial firm commitment.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds to:
- Fund the clinical development of TARA-002.
- Support the development of other clinical programs.
- Provide working capital and other general corporate purposes.
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to risks associated with the company's business and financial condition.
Investor Verification Checklist
- Verify the exact amount of underwriting discounts and commissions to calculate the precise net proceeds.
- Review the company's most recent 10-K or 10-Q for current cash balances and burn rate to assess runway extension.
- Confirm the specific timeline and milestones for the TARA-002 clinical program.
- Check for any dilution impact on existing shareholders given the issuance of 15 million new shares.